Caldeira, Gregory

About

Professor Gregory A. Caldeira is a distinguished university professor and the Dreher Chair in Political Communication and Policy Thinking at the Moritz College of Law. His academic expertise encompasses judicial processes in the United States and Europe, organized interests, and American political institutions. His research and teaching focus on these areas, with notable contributions to understanding the functioning and legitimacy of judicial systems. Professor Caldeira has an extensive publication record in prominent journals such as the American Political Science Review, American Journal of Political Science, Journal of Politics, and others. He has served on the editorial boards of several leading journals and has been actively involved in professional organizations, including the American Political Science Association and the Midwest Political Science Association, where he has held leadership roles including vice president and chair of the Section on Law and Courts. His service also includes membership on the Law and Social Science Panel of the National Science Foundation. His current research projects include analyzing the impact of landmark cases like Bush v. Gore on public support for the Supreme Court, examining the legitimacy of the European Court of Justice, conducting cross-national analyses of judicial power, and exploring the influence of organized interests on judicial agendas. Professor Caldeira's work contributes to a deeper understanding of judicial…

Research topics

• Biology
• Genetics
• Medicine
• Immunology
• Computer Science
• Cancer research
• Chemistry
• Computational biology

Selected publications

• Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations

  Blood · 2020-03-31 · 64 citations

  letterOpen access

  Lucas et al explored the clonal dynamics of chronic lymphocytic leukemia (CLL) patients following treatment and subsequent acquired resistance to ibrutinib and then venetoclax. They report different patterns of resistance mutations from previously reported changes following venetoclax treatment in the absence of prior BTK inhibitor therapy.

  PublisherOA PDFDOI

• VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia

  Leukemia · 2022 · 37 citations

  Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor complex (P-TEFb), a heterodimeric protein complex composed of cyclin dependent kinase 9 (CDK9) and cyclin T1, functions to regulate short half-life transcripts by phosphorylation of RNA Polymerase II (POLII). These transcripts are frequently dysregu…

  PublisherOA PDFDOI

• Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation

  Nature Communications · 2023 · 32 citations

  Richter's Transformation (RT) is a poorly understood and fatal progression of chronic lymphocytic leukemia (CLL) manifesting histologically as diffuse large B-cell lymphoma. Protein arginine methyltransferase 5 (PRMT5) is implicated in lymphomagenesis, but its role in CLL or RT progression is unknown. We demonstrate herein that tumors uniformly overexpress PRMT5 in patients with progression to RT. Furthermore, mice with B-specific overexpression of hPRMT5 develop a B-lymphoid expansion with incr…

  PublisherOA PDFDOI

• Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts

  NAR Genomics and Bioinformatics · 2020 · 22 citations

  1st authorCorresponding

  High-throughput short-read sequencing relies on fragmented DNA for optimal sampling of input nucleic acid. Several vendors now offer proprietary enzyme cocktails as a cheaper and more streamlined method of fragmentation when compared to acoustic shearing. We have discovered that these enzymes induce the formation of library molecules containing regions of nearby DNA from opposite strands. Sequencing reads derived from these molecules can lead to artifact-derived variant calls appearing at varian…

  PublisherOA PDFDOI

• Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease

  Journal of Clinical Medicine · 2020-07-17 · 13 citations

  articleOpen access

  Sickle-cell disease (SCD) is a debilitating hematological disorder with very few approved treatment options. Therapeutic reactivation of fetal hemoglobin (HbF) is one of the most pursued methods for ameliorating the systemic manifestations of SCD. Despite this, very few pharmacological agents have advanced to clinical trials or marketing for use. In this study, we report the development of an HbF in situ intracellular immunoblot assay coupled to a high-throughput drug screen to identify Food and…

  PublisherOA PDFDOI

Frequent coauthors

• James S. Blachly

  The Ohio State University

  17 shared

• John C. Byrd

  University of Cincinnati

  10 shared

• Jennifer A. Woyach

  The Ohio State University

  9 shared

• Katie Williams

  9 shared

• Rosa Lapalombella

  The Ohio State University

  9 shared

• Steven Sher

  The Ohio State University

  8 shared

• Larry Beaver

  8 shared

• Shelley Orwick

  The Ohio State University

  7 shared

Education

• B.A., Political Science

  University of California, Berkeley

  1983

• Other, Political Science

  University of California, Berkeley

  1985

• Ph.D., Political Science

  University of California, Berkeley

  1988

Awards & honors

• Ohio State’s Distinguished Scholar Award (1993)
• Distinguished University Professor (1998)

Similar researchers at Ohio State University

• Chang, Felixh-53
• Barnett, Kenth-15
• Alexander, Laurah-4